Immune reprogramming in the bone marrow microenvironment: a new perspective on the bone immune microenvironment of postmenopausal osteoporosis

Research on postmenopausal osteoporosis (PMOP), a common bone metabolic disease, has traditionally focused on bone loss and imbalance in bone remodeling. However, with the development of bone immunology, the complex interactions between immune cells and bone cells in the bone marrow microenvironment have gradually been revealed, and "immune reprogramming" is considered a key factor driving the persistent bone loss in PMOP. Current evidence indicates that the postmenopausal bone marrow microenvironment undergoes significant structural and functional changes. These changes are characterized by a myeloid bias in hematopoietic stem/progenitor cells, aging of bone marrow mesenchymal stem cells (BMSCs) with a tendency toward differentiation into the adipocyte lineage, an imbalance of key immune cell subpopulations such as M1 and M2 macrophages and Th17 and regulatory T cells (Treg), as well as remodeling of cytokine and chemokine axis networks. Signaling pathways such as RANK/RANKL/OPG, Wnt/β-catenin, CXCL12-CXCR4, and S1P - along with systemic factors like estrogen deficiency, inflammatory aging, and the gut-bone-immune axis-collectively shape the characteristic bone immune microenvironment of PMOP. Based on this, this article systematically reviews the changes in cell lineage and molecular mechanisms underlying PMOP bone marrow immune reprogramming. It focuses on the key signaling networks in the bone immune microenvironment and their relationship with the mechanisms of existing anti-osteoporosis drugs. Furthermore, it proposes an immunotherapy approach represented by a three-tiered framework: traditional bone-targeted drugs, immune-guided therapy, and comprehensive intervention of the bone marrow microenvironment. Finally, in conjunction with emerging technologies such as multi-omics, single-cell, and spatial omics, this article discusses future directions for constructing a PMOP bone immune map and achieving precise stratification and individualized intervention, aiming to provide a theoretical basis and methodological reference for mechanistic research and bone immune-targeted therapy of PMOP.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-02-27
DOI
https://doi.org/10.3389/fimmu.2026.1766460
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immune reprogramming in the bone marrow microenvironment: a new perspective on the bone immune microenvironment of postmenopausal osteoporosis

Xianli Zheng, D.-Q. Li, Xingwen Xie, Yuan Cheng et al.
Frontiers in Immunology
Bone Metabolism and Diseases
article

Immune reprogramming in the bone marrow microenvironment: a new perspective on the bone immune microenvironment of postmenopausal osteoporosis

Xianli Zheng, D.-Q. Li, Xingwen Xie, Yuan Cheng, Yangyang Chen, Deming Lin, Zhong Wang
article en

Abstract

Research on postmenopausal osteoporosis (PMOP), a common bone metabolic disease, has traditionally focused on bone loss and imbalance in bone remodeling. However, with the development of bone immunology, the complex interactions between immune cells and bone cells in the bone marrow microenvironment have gradually been revealed, and "immune reprogramming" is considered a key factor driving the persistent bone loss in PMOP. Current evidence indicates that the postmenopausal bone marrow microenvironment undergoes significant structural and functional changes. These changes are characterized by a myeloid bias in hematopoietic stem/progenitor cells, aging of bone marrow mesenchymal stem cells (BMSCs) with a tendency toward differentiation into the adipocyte lineage, an imbalance of key immune cell subpopulations such as M1 and M2 macrophages and Th17 and regulatory T cells (Treg), as well as remodeling of cytokine and chemokine axis networks. Signaling pathways such as RANK/RANKL/OPG, Wnt/β-catenin, CXCL12-CXCR4, and S1P - along with systemic factors like estrogen deficiency, inflammatory aging, and the gut-bone-immune axis-collectively shape the characteristic bone immune microenvironment of PMOP. Based on this, this article systematically reviews the changes in cell lineage and molecular mechanisms underlying PMOP bone marrow immune reprogramming. It focuses on the key signaling networks in the bone immune microenvironment and their relationship with the mechanisms of existing anti-osteoporosis drugs. Furthermore, it proposes an immunotherapy approach represented by a three-tiered framework: traditional bone-targeted drugs, immune-guided therapy, and comprehensive intervention of the bone marrow microenvironment. Finally, in conjunction with emerging technologies such as multi-omics, single-cell, and spatial omics, this article discusses future directions for constructing a PMOP bone immune map and achieving precise stratification and individualized intervention, aiming to provide a theoretical basis and methodological reference for mechanistic research and bone immune-targeted therapy of PMOP.

Frontiers in ImmunologyVol. 17
Gansu University of Traditional Chinese Medicine (CN), Gansu Provincial Hospital (CN)
Openalex Percentile: Top 40%
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.